IDEAYA Biosciences (IDYA) Set to Announce Earnings on Monday

IDEAYA Biosciences (NASDAQ:IDYA) is anticipated to release its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect the company to post earnings of ($1.18) per share and revenue of $7.58 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 12:30 PM ET.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.16). The business had revenue of $8.86 million for the quarter, compared to analyst estimates of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%. The business’s revenue for the quarter was up 8800.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) EPS. On average, analysts expect IDEAYA Biosciences to post ($4.52) EPS for the current fiscal year and ($4.42) EPS for the next fiscal year.

IDEAYA Biosciences Stock Performance

IDEAYA Biosciences stock opened at $31.96 on Monday. The company has a market capitalization of $2.81 billion, a P/E ratio of -16.47 and a beta of 0.08. The firm’s fifty day simple moving average is $37.24 and its 200-day simple moving average is $34.09. IDEAYA Biosciences has a 1-year low of $26.81 and a 1-year high of $42.68.

Analyst Ratings Changes

IDYA has been the subject of a number of recent research reports. Citizens Jmp reiterated a “market outperform” rating and issued a $42.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Wall Street Zen lowered IDEAYA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. William Blair assumed coverage on IDEAYA Biosciences in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Stifel Nicolaus assumed coverage on IDEAYA Biosciences in a research note on Wednesday, October 14th. They set a “buy” rating and a $48.00 price target for the company. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $50.55.

Insider Transactions at IDEAYA Biosciences

In related news, CEO Yujiro Hata sold 26,338 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the transaction, the chief executive officer directly owned 690,695 shares in the company, valued at approximately $25,838,899.95. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 4.70% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.